EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metabolomic identification of predictive and early biomarkers of cisplatin‐induced acute kidney injury in adult head and neck cancer patients

Yong Jin Lim, Steven G Xiu, M Sara Kuruvilla, Eric Winquist, Stephen Welch, Morgan Black, Lauren N Faught, Jasmine Lee, Michael J Rieder iD, Tom D Blydt-Hansen, Michael Zappitelli, Bradley L Urquhart iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.15666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Yong Jin Lim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Cisplatin, Acute Kidney Injury, Metabolomics, Biomarkers. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Western University, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Cisplatin causes acute kidney injury (AKI) in approximately one third of patients. Serum creatinine and urinary output are poor markers of cisplatin‐induced AKI. Metabolomics was utilized to identify predictive or early diagnostic biomarkers of cisplatin‐induced AKI.

Methods

Thirty‐one adult head and neck cancer patients receiving cisplatin (dose ≥70 mg/m 2 ) were recruited for metabolomics analysis. Urine and serum samples were collected prior to cisplatin (pre), 24–48 h after cisplatin (24–48 h) and 5–14 days (post) after cisplatin. Based on serum creatinine concentrations measured at the post timepoint, 11/31 patients were classified with clinical AKI. Untargeted metabolomics was performed using liquid chromatography‐mass spectrometry (LC‐MS).

Results

Metabolic discrimination was observed between “AKI” patients and “no AKI” patients at all timepoints. Urinary glycine, hippuric acid sulfate, 3‐hydroxydecanedioc acid and suberate were significantly different between AKI patients and no AKI patients prior to cisplatin infusion. Urinary glycine and hippuric acid sulfate were lower (−2.22‐fold and −8.85‐fold), whereas 3‐hydroxydecanedioc acid and suberate were higher (3.62‐fold and 1.91‐fold) in AKI patients relative to no AKI patients. Several urine and serum metabolites were found to be altered 24–48 h following cisplatin infusion, particularly metabolites involved with mitochondrial energetics.

Conclusions

We propose glycine, hippuric acid sulfate, 3‐hydroxydecanedioc acid and suberate as predictive biomarkers of predisposition to cisplatin‐induced AKI. Metabolites indicative of mitochondrial dysfunction may serve as early markers of subclinical AKI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinAcute Kidney InjuryMetabolomicsBiomarkersAntineoplastic AgentsHead and Neck NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultCreatinineChromatography, Liquid

Stichwörter der Autor:innen

acute kidney injurybiomarkercisplatinmetabolomics

Substanzen

CisplatinBiomarkersAntineoplastic AgentsCreatinine

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Division of Medical Oncology, Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Division of Nephrology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.
  • Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Division of Nephrology, Department of Pediatrics, British Columbia Children's Hospital, Vancouver, BC, Canada.

ORCID-Profile: Michael J Rieder, Bradley L Urquhart

Förderung

  • CIHR
  • Western University
  • Canadian Institutes of Health Research

Zitieren

APA

Lim, Y. J., Xiu, S. G., Kuruvilla, M. S., Winquist, E., Welch, S., Black, M., Faught, L. N., Lee, J., Rieder, M. J., Blydt-Hansen, T. D., Zappitelli, M., & Urquhart, B. L. (2024). Metabolomic identification of predictive and early biomarkers of cisplatin‐induced acute kidney injury in adult head and neck cancer patients. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15666

Vancouver

Lim YJ, Xiu SG, Kuruvilla MS, Winquist E, Welch S, Black M, et al. Metabolomic identification of predictive and early biomarkers of cisplatin‐induced acute kidney injury in adult head and neck cancer patients. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15666

BibTeX
@article{Lim2024,
  author = {Lim, Yong Jin and Xiu, Steven G and Kuruvilla, M Sara and Winquist, Eric and Welch, Stephen and Black, Morgan and Faught, Lauren N and Lee, Jasmine and Rieder, Michael J and Blydt-Hansen, Tom D and Zappitelli, Michael and Urquhart, Bradley L},
  title = {Metabolomic identification of predictive and early biomarkers of cisplatin‐induced acute kidney injury in adult head and neck cancer patients},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.15666}
}
Kostenlos starten →